NCT05899608Phase 3Recruiting

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2028-12-31Estimated

Enrollment · participants1600Estimated

Source updated2026-08-24Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2025-11-26 · 2 fields changed

Planned enrollment increased by 520 participants

− Before

~~1080 participants (planned)~~

+ After

1600 participants (planned)

Primary completion date changed

− Before

~~31 Dec 2027~~

+ After

31 Dec 2028

Check registry source

Study details

Conditions studied

Non-Small Cell Lung Cancer

Treatments or interventions studied

Ivonescimab InjectionBiological
Pembrolizumab InjectionBiological

Primary outcomes · main study measures

measure: Overall Survival (OS); description: Overall Survival (OS) in the ITT population; timeFrame: approximately 4 years; measure: Progression Free Survival (PFS); description: Progression Free Survival (PFS) assessed by investigator based on RECIST V1.1; timeFrame: approximately 3 years

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history